Clinical Trial Search

Primary: The Efficacy of Restylane Vital on Skin Structure Compared to no Treatment Using a Validated Scale. — 0.85; 2.17 units on a scale

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Reduction of Bruising — 3.74; 4.50 cm squared

Primary: The Within-subject Difference in VAS Score (Restylane Skinboosters Vital Lidocaine- Restylane Vital) at End of Injection (T0). — 32.5; 46.9 score on a scale — p=<0.0001

Primary: Number of Participants With X-ray of Either Hand With Bone Obscuration at Month 1 — 0; 0 participants

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Mean Change on Busso Hand Volume Severity Scale (BHVSS), by Hand — 2.54; 2.44; 1.72; 2.44 units on a scale — p=< 0.0001

Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001

Primary: Mean Change on Merz Hand Grading Scale (MHGS), by Hand — 2.6; 2.6; 1.5; 2.6 units on a scale — p=<0.0001

Primary: Skin Aging Measured With the Photonumeric Scale. — 21.25; 21.36; 21.21; 21.03 Units on a scale

Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale

Primary: Cochin Hand Functional Scale — 19.24 units on a scale

Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05

Primary: Proportion of Subjects With Device-and/or Injection-related Severe Treatment-emergent Adverse Events (TEAEs) in the Grade 4 Hands Group Versus the Grade 2-3 Hands Group…

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: Responder Rate Using Validated Hand Grading Scale — 73; 18; 12; 67 Participants — p=<0.0001

Primary: Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers.

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale

Primary: Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days — 0.1; 0.4 units on a scale

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale

Primary: Analysis of Elasticity (Collagen & Elastin) — 1.7; 0.5; 1.5; 0.5 units on a scale

Primary: VIO System Imaging Performance — 122 # participants with acceptable images

Primary: Skin Autofluorescence Levels at 6 Months — 3.7; 3.8 Arbitrary units

Primary: Inter-rater Reliability of Assessment of Facial Lines Using the 4-Point Facial Wrinkle Scale (FWS-A) — 0.653; 0.637; 0.647; 0.654 Kappa statistics

Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001

Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005

Primary: Measure Temperature at 3 Time Points — 29.89; 31.13; 31.87; 32.02 Degrees Celsius — p=<0.0001